Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA warns about non-GRAS cold products

This article was originally published in The Tan Sheet

Executive Summary

Boca Pharmacal markets OTCs containing prescription ingredients, making them products not generally recognized as safe and effective for use. In in a July 22 warning letter to the Coral Spring, Fla-based firm, FDA says the labels of the products - Pseudo DM GG Syrup and C-Phen DM Drops - suggest they diagnose, cure, mitigate, treat or prevent disease, although the drugs do not have approved applications. The agency adds the drugs are mislabeled for consumer use because the Rx ingredients are indicated for conditions that are not "amenable to self-diagnosis and treatment of individuals who are not medical practitioners." Boca, which contracted another firm to manufacture the products, has 15 days from receipt of the warning to notify FDA of its work to correct the violations and prevent a recurrence. The warning letter posted Sept. 20 on FDA's website does not identify the contract manufacturer

You may also be interested in...



EU Ban Looms On Cosmetic Microplastic: Time To Dig In On Biodegradable Plastic Criteria?

Biodegradable plastic alternatives for use in cosmetic products were left unaddressed, and thus arguably unusable, under the US Microbead-Free Waters Act enacted in late 2015. European industry stakeholders now face the prospect of a far more extensive microplastic ban, and the viability of bioplastics to replace conventional, petroleum-based microplastics is an area in need of work.

More GMP Warnings, Import Alerts For OTC Firms As US FDA Capped List Of Uninspected Facilities

Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.

AbbVie/Allergan Merger Edges Closer To FTC Clearance

AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.

Topics

UsernamePublicRestriction

Register

PS104535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel